FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國際商業結算控股有限公司 （於百慕達註冊成立之有限公司） 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00147 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 498,000,000,000 | HKD | | 0.001 HKD | | | 498,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 498,000,000,000 | HKD | | 0.001 HK ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公佈之內容概不負責，對其準確性或完 整性亦不發表任何聲明，且表明不會就因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED 國際商業結算控股有限公 司 （於百慕達註冊成立之有限公司） （股份代號：00147） 有關業務更新的 補充公佈 茲提述本公司日期為二零二五年八月八日、二零二五年八月二十九日、二零二五年九月十一 日、二零二五年九月十九日、二零二五年九月二十五日、二零二五年十月十六日、二零二五年 十月十七日、二零二五年十月二十二日、二零二五年十月三十一日、二零二五年十一月十日 及二零二五年十二月五日之公佈（「該等公佈」），內容有關（其中包括）本集團之加密貨幣業務 （「加密貨幣業務」）。除文義另有所指外，本公佈所用詞彙與該等公佈所界定者具有相同涵 義。 除該等公佈所提供的資料外，本公司謹此提供以下額外資料。 I. 加密貨幣業務 誠如本公司截至二零二五年三月三十一日止年度之年報所披露，本集團相信，新興金融 科技行業是未 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 國際商業結算控股有限公司 （於百慕達註冊成立之有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00147 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 498,000,000,000 | HKD | | 0.001 | HKD | | 498,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 498,000,000,000 | HKD | | 0.001 | HKD | | 498,000,000 | | 2 ...

INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.147hk.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of Current Corporate Communication. 國際商業結算控股有限公 司 (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (S ...

（股份代號：00147） INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED 國際商業結算控股有限公 司 (Incorporated in Bermuda with limited liability) (Stock Code: 00147) （於百慕達註冊成立之有限公司） NOTIFICATION LETTER 通知信函 29 December 2025 Dear Registered Shareholder, International Business Settlement Holdings Limited (the "Company") Notification of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's we ...

Financial Performance - Revenue for the six months ended September 30, 2025, was HK$38,396,000, a decrease of 64% compared to HK$106,862,000 for the same period in 2024[15]. - Gross profit for the period was HK$3,065,000, down 78% from HK$13,773,000 in the previous year[15]. - Loss before taxation increased to HK$113,364,000, compared to a loss of HK$54,427,000 in the same period last year, representing a 108% increase in losses[15]. - Loss for the period was HK$112,268,000, compared to HK$65,429,000 in the prior year, indicating a 71% increase in losses[15]. - The company reported a loss attributable to owners of the Company of HK$72,913,000, compared to a loss of HK$47,750,000 for the same period in 2024, representing a 52.7% increase in loss[16]. - Total comprehensive expense for the period was HK$116,246,000, up from HK$69,084,000 in the previous year, indicating a 68.3% increase[16]. - The company reported a basic and diluted loss per share of HK$0.36 for the six months ended September 30, 2025, compared to HK$0.24 for the same period in 2024[16]. - The loss for the period attributable to owners of the Company was HK$72,913,000 for the six months ended September 30, 2025, compared to a loss of HK$47,750,000 in 2024, indicating a deterioration in performance[86]. - The gross profit margin for the current period is 7.98%, down from 12.89% in 2024, primarily due to a shift in revenue composition towards lower-margin property management services[196]. - The loss per share for the reporting period is approximately 0.36 HK cents, compared to 0.24 HK cents in 2024[198]. Expenses and Costs - Administrative and other expenses rose significantly to HK$59,420,000, up from HK$11,264,000, marking a 429% increase[15]. - Total staff costs for the six months ended September 30, 2025, were HK$22,082,000, significantly higher than HK$7,088,000 in 2024, indicating increased investment in human resources[82]. - The cost of inventories recognized as expenses was HK$10,529,000, down from HK$29,602,000 in the previous year, suggesting improved inventory management[82]. Income and Gains - Other income, gains, and losses increased to HK$7,955,000 from HK$5,179,000, reflecting a 54% growth[15]. - Total other income, gains, and losses for the six months ended September 30, 2025, amounted to HK$7,955,000, compared to HK$5,179,000 in 2024, reflecting an increase of approximately 53.5%[72]. Assets and Liabilities - The company's net current assets improved to HK$150,119,000 as of September 30, 2025, compared to net current liabilities of HK$208,178,000 as of March 31, 2025[18]. - Total assets less current liabilities increased significantly to HK$554,057,000 from HK$169,881,000, reflecting a substantial improvement in financial position[18]. - The total carrying amount of loan receivables as of September 30, 2025, was HK$126,848,000, up from HK$124,633,000 as of March 31, 2025, reflecting an increase of 1.8%[93]. - The total completed properties held for sale as of 30 September 2025 was HK$790,818,000 (unaudited), compared to HK$809,717,000 (audited) as of 31 March 2025[112]. - Trade receivables as of 30 September 2025 were HK$143,668,000 (unaudited), a decrease from HK$146,611,000 (audited) as of 31 March 2025[115]. - The Group's digital assets held in its own wallets amounted to HK$16,220,000 (unaudited) as of 30 September 2025, with Bitcoin representing the entire amount[108]. Cash Flow - For the six months ended September 30, 2025, the operating cash flows before movements in working capital were HK$ (19,862,000), a decrease from HK$ 53,830,000 in the same period of 2024[23]. - The net cash used in operating activities for the six months was HK$ (25,942,000), compared to a net cash inflow of HK$ 8,457,000 in the previous year[23]. - Cash flows from investing activities resulted in a net cash outflow of HK$ (80,299,000), compared to HK$ (14,726,000) in the prior period[24]. - Financing activities generated a net cash inflow of HK$ 518,292,000, a significant increase from a net cash outflow of HK$ (6,627,000) in the same period last year[24]. - The total cash and cash equivalents at the end of the period were HK$ 727,609,000, up from HK$ 326,080,000 at the end of the previous period[24]. Segment Information - For the six months ended September 30, 2025, total segment revenue was HK$38,396,000, with property development contributing HK$10,861,000 and property management contributing HK$26,882,000[59]. - The cryptocurrency-related business generated revenue of HK$653,000, marking its first contribution since the segment was established[59]. - The total segment loss for the same period was HK$101,034,000, with the property development segment reporting a loss of HK$59,027,000[59]. - As of September 30, 2025, total segment assets amounted to HK$1,120,926,000, with property development assets at HK$857,821,000 and cryptocurrency-related business assets at HK$105,270,000[64]. Share Capital and Equity - The company issued shares resulting in an increase in equity attributable to owners of the Company to HK$727,964,000 as of September 30, 2025, compared to HK$302,978,000 as of April 1, 2025[19]. - The company's share capital rose to HK$23,101,000 as of September 30, 2025, up from HK$20,319,000 as of March 31, 2025, marking an increase of 8.8%[18]. - The Group issued 2,782,330,000 new ordinary shares at a subscription price of HK$0.18 per share on 30 September 2025, raising approximately HK$498,037,000 in share premium[155]. Future Outlook and Strategy - The company is focusing on expanding its cryptocurrency-related services, which are expected to grow as the market develops[56]. - The Group's management assesses that the possibility of default in mortgage loans by home buyers is remote, indicating a low risk of financial impact from guarantees provided[162]. - The Group's management reported that all loan receivables were secured by collaterals as of both September 30, 2025, and March 31, 2025[94].

Core Viewpoint - ST Xiangxue's subsidiary, Xiangxue Life Science, has received clinical trial approval for its new drug XLS-103 injection from the National Medical Products Administration, marking a significant milestone in its TCR T-cell therapy development [1] Group 1 - Xiangxue Life Science has obtained two clinical trial approval notices for XLS-103 injection, with notification numbers 2025LP03514 and 2025LP03515 [1] - The approval of XLS-103 injection is the sixth and seventh clinical trial notices related to TCR-T products developed by Xiangxue Life Science [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronic Technology Co., Ltd., for the supply of integrated circuit (IC) chips totaling 1.61 million units, valued at approximately $19.95 million (around HKD 156 million) [1] Group 1 - The agreement is part of the company's routine business operations and aims to expand its product portfolio in the computer equipment sector [1] - The company is committed to seeking business developments that enhance long-term shareholder value [1]

Core Viewpoint - International Commercial Settlement (00147.HK) announced a computer chip sales agreement with Shenzhen Nanjiguang Electronics Technology Co., Ltd. (stock code: 300940.SZ) through its wholly-owned subsidiary Hong Kong Nanjiguang Technology Co., Ltd. on December 5, 2025 [1] Group 1 - The agreement involves the sale of computer chips [1] - The partnership is expected to enhance the technological capabilities of the involved companies [1] - The agreement signifies a strategic move in the semiconductor market [1]